Incorporating regional adiposity patterns (e.g., visceral vs. subcutaneous fat distribution) and functional adiposity biomarkers (e.g., leptin/adiponectin ratio) could better elucidate the heterogeneous biological pathways through which obesity may exert differential impacts on prostate carcinogenesis and disease progression (126). The gene discussed is LEP; the disease is Obesity.